Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urogenital Neoplasms × vedolizumab × Dermatologic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Dermatologic 1

Conditions

Melanoma 3 Carcinoma, Non-Small-Cell Lung 2 Urogenital Neoplasms 1 Colitis 1

Interventions

atezolizumab 2 vedolizumab 1 Taste 1 Radiotherapy 1 Loperamide 1 LDP-02 1 Interleukin-2 1 Infliximab 1 Immunotherapy 1 Immunoglobulin G 1 Fecal Microbiota Transplantation 1 Drug Therapy 1 Disulfides 1 CT-P13 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡